191 related articles for article (PubMed ID: 12539990)
1. Management of hyperlipidemia in the elderly population: an evidence-based approach.
Dalal D; Robbins JA
South Med J; 2002 Nov; 95(11):1255-61. PubMed ID: 12539990
[TBL] [Abstract][Full Text] [Related]
2. Primary prevention of coronary heart disease in the elderly.
Dornbrook-Lavender KA; Pieper JA; Roth MT
Ann Pharmacother; 2003 Nov; 37(11):1654-63. PubMed ID: 14565805
[TBL] [Abstract][Full Text] [Related]
3. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
Sever PS
Am J Med; 2005 Dec; 118 Suppl 12A():3-9. PubMed ID: 16356801
[TBL] [Abstract][Full Text] [Related]
4. Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents.
Dupuy AM; Carrière I; Scali J; Cristol JP; Ritchie K; Dartigues JF; Gambert P; Ancelin ML
Climacteric; 2008 Feb; 11(1):74-83. PubMed ID: 18202967
[TBL] [Abstract][Full Text] [Related]
5. Optimal management of cholesterol levels and the prevention of coronary heart disease in women.
Mosca LJ
Am Fam Physician; 2002 Jan; 65(2):217-26. PubMed ID: 11820486
[TBL] [Abstract][Full Text] [Related]
6. Reducing the risk of coronary heart disease via lipid reduction.
Spratt KA
J Am Osteopath Assoc; 2004 Sep; 104(9 Suppl 7):S9-13. PubMed ID: 15467018
[TBL] [Abstract][Full Text] [Related]
7. The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient.
Ong HT
QJM; 2005 Aug; 98(8):599-614. PubMed ID: 16006501
[TBL] [Abstract][Full Text] [Related]
8. Secondary prevention of coronary heart disease in the elderly.
Dornbrook-Lavender KA; Roth MT; Pieper JA
Ann Pharmacother; 2003 Dec; 37(12):1867-76. PubMed ID: 14632542
[TBL] [Abstract][Full Text] [Related]
9. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
[TBL] [Abstract][Full Text] [Related]
10. Primary prevention of coronary heart disease in women.
Rees M; Stevenson J;
Menopause Int; 2008 Mar; 14(1):40-5. PubMed ID: 18380961
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
12. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
13. [Hyperlipidemia in the elderly].
Kawano M
Nihon Rinsho; 2002 May; 60(5):1017-23. PubMed ID: 12029980
[TBL] [Abstract][Full Text] [Related]
14. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
Yokoyama M; Origasa H;
Am Heart J; 2003 Oct; 146(4):613-20. PubMed ID: 14564313
[TBL] [Abstract][Full Text] [Related]
15. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL
Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061
[TBL] [Abstract][Full Text] [Related]
16. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
[TBL] [Abstract][Full Text] [Related]
17. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
[TBL] [Abstract][Full Text] [Related]
18. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of lipid-lowering treatment according to lipid level.
Pilote L; Ho V; Lavoie F; Coupal L; Zowall H; Grover SA
Can J Cardiol; 2005 Jun; 21(8):681-7. PubMed ID: 16003451
[TBL] [Abstract][Full Text] [Related]
20. Protecting the heart: a practical review of the statin studies.
Ong HT
MedGenMed; 2002 Dec; 4(4):1. PubMed ID: 12817199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]